Tirzepatide slashes alcohol intake in animal tests—could it curb human addiction?

A recent study from the University of Gothenburg suggests that tirzepatide, the drug behind the diabetes medication Mounjaro, could help reduce alcohol consumption. Tests on animal models showed a sharp drop in voluntary drinking and binge episodes. Yet, despite promising results, no clinical trials for alcohol dependence have been submitted to major regulators like the EMA or FDA.

The research found that tirzepatide cut voluntary alcohol intake by over 50% in animal tests. Episodes of binge drinking also fell dramatically. Scientists believe the drug works by altering the brain's reward system, weakening the dopamine response linked to alcohol cravings.

Tirzepatide differs from similar medications because it targets two receptors—GIP and GLP-1—rather than one. This dual action may give it a stronger effect on addictive behaviour than drugs like semaglutide. Early findings also suggest it could trigger long-term biological changes in the brain, potentially reducing addictive tendencies through epigenetic modifications.

While these results offer a new approach to treating alcohol dependence, human trials have not yet begun. The drug's existing approval for diabetes might speed up the regulatory process. Still, no formal applications for alcohol dependence studies have been filed with the EMA or FDA.

Tirzepatide's impact on alcohol consumption in animals raises hopes for future treatment options. The next step depends on human trials to confirm its safety and effectiveness. Until then, approval for use in alcohol dependence remains uncertain.